MedPath

Study of Infliximab Therapy for IVIG Treatment-resistant Kawasaki Disease.

Completed
Conditions
Kawasaki Disease
Registration Number
JPRN-jRCT1091220086
Lead Sponsor
Investigator-initiated Clinical Research (in-house)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria

Patients against IVIG Treatment-resistant Kawasaki Disease (less than 37.5 degrees C within a 24-hour period)

Exclusion Criteria

Past History of Demyelinating Disease
Patients less than 6 months of taking BCG
Patients with lung thberculosis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complication of Coronary Artery Aneurysm after Infliximab Injection
Secondary Outcome Measures
NameTimeMethod
Complication of Coronary Artery Aneurysm after Injection (up to One year after Injection) <br>Pyretolysis (within a 48-hour period after injection)<br>Adverse Event
© Copyright 2025. All Rights Reserved by MedPath